US Pharma MarketingRoche signs trispecific T cell engager pact with Simcere in another China deal
Roche licenses Simcere Zaiming Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug…
For the second time in as many weeks, Roche's business development team has lined up a deal with a Chinese biopharma.
The Swiss drug giant this time is teaming with Simcere Zaiming on a preclinical ...
Source: Endpoints News